- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Results
4
Companies which are potentially undervalued and in an acceptable financial position.
4 companies
Tecan Group
Market Cap: CHF 1.7b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 134.80
7D
-4.7%
1Y
-8.9%
Roche Holding
Market Cap: CHF 250.2b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 313.10
7D
-1.2%
1Y
21.3%
Novartis
Market Cap: CHF 220.5b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 115.58
7D
-2.3%
1Y
27.2%
Siegfried Holding
Market Cap: CHF 3.5b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 81.00
7D
-3.0%
1Y
-11.6%